Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Stemcentrx
Biotech
AbbVie's ADC fails in phase 3 brain tumor test
AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.
Ben Adams
May 17, 2019 11:00am
Allergan taps Celgene vet for M&A guidance—Chutes & Ladders
Mar 29, 2019 9:30am
AstraZeneca offers $6.9B for a Daiichi Sankyo cancer drug
Mar 29, 2019 4:55am
Pain intensifies for AbbVie as it slashes 178 jobs from Stemcentrx
Mar 28, 2019 11:50am
AbbVie takes $4B hit on Rova-T failures
Jan 7, 2019 11:18am
AbbVie halts trial of Stemcentrx ADC for cancer
Apr 30, 2018 8:10am
